|
 |
Tizanidine HydrochlorideThis page contains recent news articles, when available, and an overview of Tizanidine Hydrochloride but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release), Acorda Therapeutics, Inc. Announces Pricing of Common Stock Offering - Aug 7, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. MarketWatch Acorda Therapeutics to Host Conference Call to Report Second ... - Jul 29, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Centre Daily Times, Acorda Therapeutics CEO Ron Cohen Appointed Member of Executive ... - Jun 20, 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release), Financialbusinessnews.us: Todays Stock News: WTWO, ACOR, CYTX, NEXC - Jun 20, 2008 The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Trading Markets (press release), Acorda Therapeutics Announces Positive Data from Second Phase 3 ... - 02 Jun 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Business Wire (press release), Acorda Therapeutics Reports First Quarter 2008 Financial Results - May 5, 2008 Zanaflex(R) (tizanidine hydrochloride) Gross Sales - For the quarter ended March 31, 2008, the Company reported gross sales of Zanaflex Capsules(R) FOXBusiness NovaDel Announces Positive Data from Pilot Pharmacokinetic Study ... - Apr 7, 2008 This Pilot Pharmacokinetic Study was designed to compare the PK profile of 2 mg, 4 mg and 8 mg Oral Spray (OS) doses of tizanidine hydrochloride to a 4 mg Business Wire (press release), Acorda Therapeutics Names John Librie Senior Vice President, Sales ... - Apr 3, 2008 Mr. Librie will continue to manage the sales and marketing efforts of Zanaflex Capsules(R) (tizanidine hydrochloride), as well as oversee all pre-commercial FOXBusiness NovaDel Pharma Says Tizanidine Oral Spray Shows Greater ... - Apr 7, 2008 The study was designed to compare the pharmacokinetic profile of 2 mg, 4 mg and 8 mg OS doses of tizanidine hydrochloride to a 4 mg Zanaflex tablet. RTT News, Acorda Therapeutics to Present at the Cowen and Company 28th ... - Mar 10, 2008 ...including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules(R) (tizanidine hydrochloride), the risk of unfavorable results Centre Daily Times, Acorda Therapeutics Reports Fourth Quarter and Full Year 2007 ... - Feb 11, 2008 For the fourth quarter ended December 31, 2007, the Company reported gross sales of Zanaflex Capsules (tizanidine hydrochloride) of $11.8 million and gross StreetInsider.com (subscription), Acorda Therapeutics, Inc. Announces Proposed Public Offering of ... - Feb 6, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. FOXBusiness Acorda Therapeutics Reports Third Quarter 2007 Financial Results - Nov 6, 2007 6455557 relating to multiparticulate tizanidine compositions, such as those sold by the Company as Zanaflex Capsules TM (tizanidine hydrochloride). Business Wire (press release), Acorda Therapeutics CEO Inducted into Spinal Cord Injury Hall of Fame - Nov 9, 2007 The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. WELT ONLINE, Acorda Therapeutics Files Lawsuit Against Apotex Corp. and Apotex ... - Oct 11, 2007 The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. WELT ONLINE, ACOR: Files Patent Infringement Lawsuit vs Apotex re Generic ... - Oct 12, 2007 ...to the FDA seeking marketing approval for generic versions of the Company's three Zanaflex Capsules(TM) (tizanidine hydrochloride) dosage strengths. Trading Markets (press release), Acorda Therapeutics Announces Receipt of ANDA Filing for Zanaflex ... - Sep 5, 2007 The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Die Welt, Acorda Therapeutics to Host Conference Call and Webcast to Report ... - Jul 31, 2007 Business Wire (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda Therapeutics Announces Exercise of Option by Underwriters - 06 Jul 2007 Business Wire (press release),The Company's marketed products include Zanaflex Capsules TM (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda Therapeutics to Present at Friedman, Billings, Ramsey & Co ... - May 24, 2007 PharmaLive.com (press release),The Company's marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride), a short-acting drug for the management of spasticity. FDA MedWatch: Zanaflex (tizanidine hydrochloride) Tablets and ... - Apr 12, 2007 PharmaLive.com (press release),The letter will he sent to physicians who have prescribed iizanidine hydrochloride, and pharmacists who have ordered tizanidine hydrochloride, Acorda Therapeutics to Host Analyst and Investor Reception - Apr 25, 2007 Business Wire (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda Therapeutics to Present at 7th Annual Fortis Biotech Conference - Apr 18, 2007 Genetic Engineering News (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda Therapeutics Announces Completion of Zanaflex Capsules ... - Jan 8, 2007 PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. Acorda Therapeutics Elects Barry Greene, COO of Alnylam, to its ... - Jan 8, 2007 Business Wire (press release),The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda Therapeutics to Receive Up to $10 Million from Paul Capital ... - Nov 29, 2006 PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda Therapeutics Reports Third Quarter 2006 Financial Results Nov 2, 2006 For the quarter ended September 30, 2006, gross sales of Zanaflex Capsules(TM) (tizanidine hydrochloride) were $5.0 million and gross sales of Zanaflex(R ... -Genetic Engineering News (press release), Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles Nov 3, 2006 Acorda’s marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets. ... -Business Wire (press release), Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) ... Oct 17, 2006 ...high-volume prescribers. The Acorda sales team promotes Zanaflex Capsules(TM) (tizanidine hydrochloride). "This second expansion ... -Genetic Engineering News (press release), Acorda Therapeutics to Host Conference Call to Report Third ... Oct 26, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Business Wire (press release), Acorda Therapeutics to Present at the BioCentury Newsmakers in the ... Aug 31, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Business Wire Acorda Therapeutics Reports Second Quarter 2006 Financial Results Aug 3, 2006 For the quarter ended June 30, 2006, gross sales were $3.9 million for Zanaflex Capsules(TM) (tizanidine hydrochloride) and $4.0 million for Zanaflex(R ... -Genetic Engineering News Acorda Therapeutics Announces Directors Stepping Down Aug 7, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Genetic Engineering News Acorda Therapeutics to Host Analyst and Investor Day Jul 6, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Genetic Engineering News Acorda Therapeutics Reports First Quarter 2006 Financial Results May 5, 2006 For the quarter ended March 31, 2006, gross sales of Zanaflex Capsules(TM) (tizanidine hydrochloride) were $2.3 million and gross sales of Zanaflex(R) tablets ... - Genetic Engineering News Acorda Therapeutics to Present at Two Upcoming Conferences May 8, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... - Genetic Engineering News Acorda Therapeutics Reports First Quarter 2006 Financial Results May 5, 2006 For the quarter ended March 31, 2006, gross sales of ZanaflexCapsules(TM) (tizanidine hydrochloride) were $2.3 million and grosssales of Zanaflex(R) tablets ... - Finanzen.net Acorda Therapeutics, Inc. [ACOR] President & CEO to Ring The ... Apr 6, 2006 The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... - Market Wire Acorda Therapeutics Reports Fourth Quarter and Full Year 2005 ... Mar 31, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... - Genetic Engineering News Acorda Therapeutics(R) Announces Completion of Enrollment in ... Mar 3, 2006 Acorda also announced that it has expanded its in-house, specialty sales force for Zanaflex Capsules(TM) (tizanidine hydrochloride) from 14 to 32. ... - Genetic Engineering News, Paul Royalty Fund Purchases Revenue Interest in Acorda's Zanaflex ... Jan 19, 2006 Both products contain tizanidine hydrochloride, or tizanidine, one of the two leading treatments currently used for the management of spasticity. ... - Yahoo! News : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |